Moderate Evidence
Research Overview
Zelenectide Pevedotin Research for Pancreatic Cancer
An overview of research and source records on Zelenectide Pevedotin in the context of pancreatic cancer.
Research Summary
Under investigation in Phase 1/2 expansion cohorts due to high Nectin-4 expression (60-80%). No tumor-specific response rate has been reported yet (the Phase 1 Duravelo-1 dose-escalation reported only a pooled all-tumor ORR). Limited data available; ongoing evaluation.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.